Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10Gynecologic 5Thoracic 3Head & Neck 3Other solid neoplasm 1NET 1Lymphoid 1Genitourinary 1Endocrine 1Dermatologic 1Breast 1

Conditions

Melanoma 14Neoplasms 5Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Uveal Melanoma 2Thyroid Neoplasms 2Skin Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Skin Diseases 1Sezary Syndrome 1Rectal Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Multiple Myeloma 1

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Parkinson Disease 4, Autosomal Dominant Lewy Body × Dermatologic × Clear all
NCT03553836 2024-11-29

KEYNOTE-716

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
976 enrolled 15 charts 1 FDA
Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡